ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Viability Testing and Transplantation of Marginal Donor Livers (VITTAL) Trial: Metabolomics of Ex Vivo Normothermically Machine Perfused Livers Discloses Molecular Signatures Predictive of Graft Viability and Post Transplant Outcomes

J. Attard1, W. Dunn2, L. Wallace1, R. Laing1, Y. Boteon1, H. Mergental3, D. Mirza3, T. Perera3, S. Afford1

1CLGR, University of Birmingham and NIHR Biomedical Research Centre, Birmingham, United Kingdom, 2Phenome Centre Birmingham, University of Birmingham, Birmingham, United Kingdom, 3Liver Unit, Queen Elizabeth University Hospital, Birmingham, United Kingdom

Meeting: 2019 American Transplant Congress

Abstract number: 60

Keywords: Liver metabolism, Liver transplantation, Machine preservation

Session Information

Session Name: Concurrent Session: Biomarkers, Immune Monitoring and Outcomes I

Session Type: Concurrent Session

Date: Sunday, June 2, 2019

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:42pm-3:54pm

Location: Room 306

*Purpose: Donor organ shortage has led to increased reliance on high-risk livers for transplantation. Furthermore, emergence of machine perfusion has led to a paradigm shift in organ preservation from functional suppression in static cold storage to full ex vivo metabolic support. The recently completed VITTAL trial demonstrated that normothermic machine perfusion (NMP-L) provides an opportunity to objectively assess graft quality and functional integrity pre-transplantation in order to safely transplant high-risk livers turned down by all transplant centres. This study investigated the potential of metabolic profiling to elucidate molecular signatures during NMP-L predictive of graft viability, post-reperfusion syndrome (PRS) and early allograft dysfunction (EAD) in these discarded livers.

*Methods: All livers were deemed marginal according to established high-risk criteria, and had been discarded by all transplant centres. 31 livers underwent NMP-L for a minimum of four hours, at which point a decision was made to transplant based on established viability criteria. Perfusate aliquots from commencement of graft perfusion to 4-hour time point were collected from all livers. Samples were centrifuged and the supernatant subjected to an untargeted metabolomics analysis using Ultra High Performance Liquid Chromatography-Mass Spectrometry.

*Results: 22 livers were transplanted after achieving viability criteria. Univariate statistical analyses revealed more than 20 metabolites (q<0.05) differentiating liver metabolic profiles according to viability criteria fulfilment following 4 hours of perfusion. Key changes were detected in metabolites relating to lipid, phospholipid and sphingolipid metabolism, notably upregulated in the non-viable group. In the transplanted cohort; 52 metabolites distinguished EAD (n=7) from non-EAD livers (n=15) after 4 hours of perfusion. The PRS group (n=10) revealed changes in 36 metabolites after 4 hours of perfusion compared to non-PRS group (n=12).

*Conclusions: This study reveals a metabolic signature of high-risk livers that correlates with VITTAL criteria for graft viability for transplantation during NMP-L. It also demonstrates the potential of NMP-L metabolic profiling as a clinical tool to objectively assess the quality and predict functional integrity of these livers pre-implantation.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Attard J, Dunn W, Wallace L, Laing R, Boteon Y, Mergental H, Mirza D, Perera T, Afford S. Viability Testing and Transplantation of Marginal Donor Livers (VITTAL) Trial: Metabolomics of Ex Vivo Normothermically Machine Perfused Livers Discloses Molecular Signatures Predictive of Graft Viability and Post Transplant Outcomes [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/viability-testing-and-transplantation-of-marginal-donor-livers-vittal-trial-metabolomics-of-ex-vivo-normothermically-machine-perfused-livers-discloses-molecular-signatures-predictive-of-graft-viabi/. Accessed May 18, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences